Top

Published in:

Open Access 01-12-2024 | Type 2 Diabetes | Research

The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis

Authors: Binura Taurbekova, Kymbat Mukhtarova, Zhandos Salpynov, Kuralay Atageldiyeva, Antonio Sarria-Santamera

Published in: BMC Nephrology | Issue 1/2024

Abstract

Background

Globally, diabetic kidney disease (DKD) has become the leading cause of end-stage renal disease, imposing substantial social and economic costs. This meta-analysis was designed to provide valuable insights into gene-disease interactions by investigating the potential association between lipid metabolism gene polymorphisms and the risk of DKD.

Methods

An electronic literature search was conducted on MEDLINE Complete, Web of Science, Embase, and PubMed. A total of 18 studies on the peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala variant and 20 publications concerning apolipoprotein E (ApoE) gene polymorphism were included in the meta-analysis.

Results

Overall, the PPARγ Pro12Ala polymorphism was found to be significantly associated with a decreased DKD risk (OR = 0.74, 95% CI: 0.62–0.88). In subgroup analysis, Ala carriers were less susceptible to DKD than Pro homozygotes among Asian (OR = 0.73, 95% CI: 0.56–0.95) and Caucasian populations (OR = 0.74, 95% CI: 0.59–0.93). Subgroup analysis stratified by albuminuria categories showed that the PPARγ Pro12Ala polymorphism reduced the risk of both microalbuminuria and macroalbuminuria with corresponding ORs of 0.58 (95% CI: 0.43–0.78) and 0.68 (95% CI: 0.53–0.86). Sensitivity analysis confirmed the robustness of the meta-analysis results. However, publication bias was identified in the subgroup analysis of the Caucasian population. The primary analysis of the ApoE gene polymorphism yielded significant findings, indicating that ApoE ε2/ε2, ApoE ε2/ε3, and ApoE ε2/ε4 genotypes increase the risk of DKD (ε2/ε2 vs. ε3/ε3: OR = 1.93, 95% CI: 1.03–3.61; ε2/ε3 vs. ε3/ε3: OR = 1.63, 95% CI: 1.19–2.25; ε2/ε4 vs. ε3/ε3: OR = 1.87, 95% CI: 1.37–2.55). However, sensitivity analysis suggested that influential and Hardy-Weinberg equilibrium (HWE)-violating studies may impact the overall effect estimates.

Conclusions

A meta-analysis showed that PPARγ gene polymorphism may be a protective factor for DKD, whereas the ApoE ε2/ε2, ApoE ε2/ε3, and ApoE ε2/ε4 genotypes are associated with an increased risk of DKD. However, the role of ApoE gene polymorphism in susceptibility to DKD is less certain and requires further evaluation.

Available only for authorised users

Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1–17. https://doi.org/10.1155/2021/1497449.CrossRef

Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102(2):248–60. https://doi.org/10.1016/j.kint.2022.05.012.CrossRefPubMed

Zheng L, Chen X, Luo T, Ran X, Hu J, Cheng Q, Yang S, Wu J, Li Q, Wang Z. Early-onset type 2 diabetes as a risk factor for end-stage renal disease in patients with diabetic kidney disease. Prev Chronic Dis. 2020;17:E50. https://doi.org/10.5888/pcd17.200076.CrossRefPubMedPubMedCentral

Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7(6):327–40. https://doi.org/10.1038/nrneph.2011.51.CrossRefPubMed

Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. Kidney Dis (Basel). 2017;3(4):171–80. https://doi.org/10.1159/000479874.CrossRefPubMed

Agarwal R. Pathogenesis of diabetic nephropathy. ADA Clin Compendia. 2021;2021(1):2–7. https://doi.org/10.2337/db20211-2.CrossRef

Cataldi S, Costa V, Ciccodicola A, Aprile M. PPARγ and diabetes: beyond the genome and towards personalized medicine. Curr Diab Rep. 2021;21(6):18. https://doi.org/10.1007/s11892-021-01385-5.CrossRefPubMed

Shafi S, Khurana N, Gupta J. PPAR gamma agonistic activity of dillapiole: protective effects against diabetic nephropathy. Nat Prod Res. 2024:1–6. https://doi.org/10.1080/14786419.2024.2334323

Tiongco RE, Basilio H, Camacho DR, Ellorin WM, Sico CA, Arceo E. Association of the rs3856806 polymorphism in the PPARG gene with type 2 diabetes mellitus: a meta-analysis of 11,811 individuals. Lab Med. 2023;54(2):193–8. https://doi.org/10.1093/labmed/lmac095.CrossRefPubMed

10.

Kasim NB, Huri HZ, Vethakkan SR, Ibrahim L, Abdullah BM. Genetic polymorphisms associated with overweight and obesity in uncontrolled type 2 diabetes mellitus. Biomark Med. 2016;10(4):403–15. https://doi.org/10.2217/bmm-2015-0037.CrossRefPubMed

11.

Mansoori A, Amini M, Kolahdooz F, Seyedrezazadeh E. Obesity and Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma gene in healthy adults: a systematic review and meta-analysis. Ann Nutr Metab. 2015;67(2):104–18. https://doi.org/10.1159/000439285.CrossRefPubMed

12.

Sarhangi N, Sharifi F, Hashemian L, Hassani Doabsari M, Heshmatzad K, Rahbaran M, Jamaldini SH, Aghaei Meybodi HR, Hasanzad M. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12764. https://doi.org/10.1038/s41598-020-69363-7.CrossRefPubMedPubMedCentral

13.

Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284–7. https://doi.org/10.1038/3099.CrossRefPubMed

14.

Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268(1):178–82. https://doi.org/10.1006/bbrc.2000.2096.CrossRefPubMed

15.

Chen YN, Wang PW, Tung SC, Kuo MC, Weng SW, Chou CK, Chang CM, Tsa CJ, Taso CF, Shen FC, Chen JF. Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy. J Diabetes Investig. 2020;11(4):923–9. https://doi.org/10.1111/jdi.13208.CrossRefPubMedPubMedCentral

16.

Lapice E, Monticelli A, Cocozza S, Pinelli M, Cocozza S, Bruzzese D, Riccardi G, Vaccaro O. The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes. J Transl Med. 2015;13:85. https://doi.org/10.1186/s12967-015-0448-6.CrossRefPubMedPubMedCentral

17.

Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H. Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care. 2012;35(6):1388–93. https://doi.org/10.2337/dc11-2142.CrossRefPubMedPubMedCentral

18.

Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, Li L, Jiang J, Zhao W. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care. 2010;33(1):144–9. https://doi.org/10.2337/dc09-1258.CrossRefPubMed

19.

De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P, BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes. 2009;58(12):2920–9. https://doi.org/10.2337/db09-0407.CrossRefPubMedPubMedCentral

20.

Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003;52(12):3010–3. https://doi.org/10.2337/diabetes.52.12.3010.CrossRefPubMed

21.

Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002;51(8):2653–7. https://doi.org/10.2337/diabetes.51.8.2653.CrossRefPubMed

22.

Hashemian L, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk. J Diabetes Metab Disord. 2021;20(2):1385–90. https://doi.org/10.1007/s40200-021-00872-6.CrossRefPubMedPubMedCentral

23.

Regine I, Husain RSRA, Aswathi RP, Reddy DR, Ahmed SSSJ, Ramakrishnan V. Association between PPARγrs1801282 polymorphism with diabetic nephropathy and type-2 diabetes mellitus susceptibility in south India and a meta-analysis. Nefrologia. 2020;40(3):287–98. https://doi.org/10.1016/j.nefro.2020.01.005.CrossRefPubMed

24.

Liu G, Zhou TB, Jiang Z, Zheng D, Yuan F, Li Y, Hu H, Chen Z. Relationship between PPARγ Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: results from a meta-analysis. J Recept Signal Transduct Res. 2014;34(2):131–6. https://doi.org/10.3109/10799893.2013.864678.CrossRefPubMed

25.

Bhaskar LV, Mahin S, Ginila RT, Soundararajan P. Role of the ACE ID and PPARG P12A polymorphisms in genetic susceptibility of diabetic nephropathy in a south Indian population. Nephrourol Mon. 2013;5(3):813–7. https://doi.org/10.5812/numonthly.9573.CrossRefPubMedPubMedCentral

26.

Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine. 2020;59:102954. https://doi.org/10.1016/j.ebiom.2020.102954.CrossRefPubMedPubMedCentral

27.

Seripa D, D’Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011;14(5):491–500. https://doi.org/10.1089/rej.2011.1169.CrossRefPubMed

28.

Wolters FJ, Yang Q, Biggs ML, Jakobsdottir J, Li S, Evans DS, et al. The impact of APOE genotype on survival: results of 38,537 participants from six population-based cohorts (E2-CHARGE). PLoS ONE. 2019;14(7):e0219668. https://doi.org/10.1371/journal.pone.CrossRefPubMedPubMedCentral

29.

Ghebranious N, Ivacic L, Mallum J, Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res. 2005;33(17):e149. https://doi.org/10.1093/nar/gni155.CrossRefPubMedPubMedCentral

30.

Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66(9):616 – 23. https://doi.org/10.1002/iub.1314. PMID: 25328986.

31.

Xue H, Zhang M, Liu J, Wang J, Ren G. Structure-based mechanism and inhibition of cholesteryl ester transfer protein. Curr Atheroscler Rep. 2023;25(4):155–66. https://doi.org/10.1007/s11883-023-01087-1.CrossRefPubMedPubMedCentral

32.

Russo GT, Horvath KV, Di Benedetto A, Giandalia A, Cucinotta D, Asztalos B. Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes. Atherosclerosis. 2010;210(1):294–301. https://doi.org/10.1016/j.atherosclerosis.2009.11.011.CrossRefPubMed

33.

Huang YC, Chen SY, Liu SP, Lin JM, Lin HJ, Lei YJ, Chung YC, Chen YC, Wang YH, Liao WL, Tsai FJ. Cholesteryl Ester transfer protein genetic variants associated with risk for type 2 diabetes and diabetic kidney disease in Taiwanese population. Genes (Basel). 2019;10(10):782. https://doi.org/10.3390/genes10100782.CrossRefPubMed

34.

Russo GT, Giandalia A, Romeo EL, Muscianisi M, Ruffo MC, Alibrandi A, Bitto A, Forte F, Grillone A, Asztalos B, Cucinotta D. HDL subclasses and the common CETP TaqIB variant predict the incidence of microangiopatic complications in type 2 diabetic women: a 9years follow-up study. Diabetes Res Clin Pract. 2017;132:108–17. https://doi.org/10.1016/j.diabres.2017.07.026.CrossRefPubMed

35.

McKay GJ, Savage DA, Patterson CC, Lewis G, McKnight AJ, Maxwell AP. Association analysis of dyslipidemia-related genes in diabetic nephropathy. PLoS ONE. 2013;8(3):e58472. https://doi.org/10.1371/journal.pone.0058472.CrossRefPubMedPubMedCentral

36.

Hadjadj S, Gallois Y, Simard G, Bouhanick B, Passa P, Grimaldi A, Drouin P, Tichet J, Marre M. Lack of relationship in long-term type 1 diabetic patients between diabetic nephropathy and polymorphisms in apolipoprotein epsilon, lipoprotein lipase and cholesteryl ester transfer protein. Nephrol Dial Transpl. 2000;15(12):1971–6. https://doi.org/10.1093/ndt/15.12.1971.CrossRef

37.

Kumari A, Kristensen KK, Ploug M, Winther AL. The importance of lipoprotein lipase regulation in atherosclerosis. Biomedicines. 2021;9(7):782. https://doi.org/10.3390/biomedicines9070782.CrossRefPubMedPubMedCentral

38.

Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesaniemi YA. DNA polymorphisms at the lipoprotein lipase gene are associated with macroangiopathy in type 2 (non-insulin-dependent) diabetes mellitus. Atherosclerosis. 1995;115:99–105. https://doi.org/10.1016/0021-9150(94)05504-c.CrossRefPubMed

39.

Mattu RK, Trevelyan J, Needham EW, Khan M, Adiseshiah MA, Richter D, Murray RG, Betteridge DJ. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in type II diabetes. Diabetologia. 2002;45:905–13. https://doi.org/10.1007/s00125-002-0824-7.CrossRefPubMed

40.

Solini A, Passaro A, Fioretto P, Nannipieri M, Ferrannini E. Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. J Intern Med. 2004;256:30–6. https://doi.org/10.1111/j.1365-2796.2004.01332.x.CrossRefPubMed

41.

Ng MC, Baum L, So WY, Lam VK, Wang Y, Poon E, Tomlinson B, Cheng S, Lindpaintner K, Chan JC. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T > C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet. 2006;70:20–8. https://doi.org/10.1111/j.1399-0004.2006.00628.x.CrossRefPubMed

42.

Riancho JA, Vázquez L, García-Pérez MA, Sainz J, Olmos JM, Hernández JL, Pérez-López J, Amado JA, Zarrabeitia MT, Cano A, Rodríguez-Rey JC. Association of ACACB polymorphisms with obesity and diabetes. Mol Genet Metab. 2011;104(4):670–6. https://doi.org/10.1016/j.ymgme.2011.08.013.CrossRefPubMed

43.

Thongnak L, Pongchaidecha A, Lungkaphin A. Renal lipid metabolism and lipotoxicity in diabetes. Am J Med Sci. 2020;359(2):84–99. https://doi.org/10.1016/j.amjms.2019.11.004.CrossRefPubMed

44.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

45.

Wells G, Shea B, O’Connell D, Peterson J et al. May,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 3 2021.

46.

Li T, Shi Y, Yin J, Qin Q, Wei S, Nie S, Liu L. The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis. Int Urol Nephrol. 2015;47(1):117–30. https://doi.org/10.1007/s11255-014-0843-6.CrossRefPubMed

47.

Tziastoudi M, Stefanidis I, Zintzaras E. The genetic map of diabetic nephropathy: evidence from a systematic review and meta-analysis of genetic association studies. Clin Kidney J. 2020;13(5):768–81. https://doi.org/10.1093/ckj/sfaa077.CrossRefPubMedPubMedCentral

48.

Gan C, Zhang Y, Zhang X, Huang Q, Guo X. Association of apolipoprotein E gene polymorphism with type 2 diabetic nephropathy in the southern Chinese population. Int J Gen Med. 2023;16:5549–58. https://doi.org/10.2147/IJGM.S440103.CrossRefPubMedPubMedCentral

49.

Jiang Y, Ma L, Han C, Liu Q, Cong X, Xu Y, Zhao T, Li P, Cao Y. Effects of apolipoprotein E isoforms in diabetic nephropathy of Chinese type 2 diabetic patients. J Diabetes Res. 2017;2017:3560920. https://doi.org/10.1155/2017/3560920.CrossRefPubMedPubMedCentral

50.

Atta MI, Abo Gabal K, El-Hadidi K, Swellam M, Genina A, Zaher NF. Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients. IUBMB Life. 2016;68(1):58–64. https://doi.org/10.1002/iub.1460.CrossRefPubMed

51.

Akarsu E, Pirim I, Capoglu I, Kaya H, Alcay G, Unuvar N. A relation between the apolipoprotein E genotypes and microalbuminuria in type 2 diabetes mellitus. Turk J Med Sci. 2001;31(1):59–64.

52.

Horita K, Eto M, Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis. 1994;107(2):203–11. https://doi.org/10.1016/0021-9150(94)90021-3.CrossRefPubMed

53.

Atageldiyeva KK, Nemr R, Echtay A, Racoubian E, Sarray S, Almawi WY. Apolipoprotein E genetic polymorphism influence the susceptibility to nephropathy in type 2 diabetes patients. Gene. 2019;715:144011. https://doi.org/10.1016/j.gene.2019.144011.CrossRefPubMed

54.

Mohamed SH, Allam HM, Kamel AA, Hussein MHS. Association of PPARγ gene polymorphism in Type-2 diabetes Mellitus and its relation to Diabetic kidney disease. NeuroQuantology. 2022;20(10):5517–30. https://doi.org/10.14704/nq.2022.20.10.NQ55531.CrossRef

55.

Ahmed AI, Osman NA, NasrAllah MM, Kamal MM. The association between diabetic nephropathy and polymorphisms in PPARγ pro 12Ala and CCR5δ 32 genes in type 2 diabetes. Egypt J Intern Med. 2013;25(1):10–4. https://doi.org/10.7123/01.EJIM.0000425954.57680.ee.CrossRef

56.

De Cosmo S, Prudente S, Lamacchia O, Lapice E, Morini E, Di Paola R, Copetti M, Ruggenenti P, Remuzzi G, Vaccaro O, Cignarelli M, Trischitta V. PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transpl. 2011;26(12):4011–6. https://doi.org/10.1093/ndt/gfr187.CrossRef

57.

Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transpl. 2009;24(11):3360–6. https://doi.org/10.1093/ndt/gfp271.CrossRef

58.

Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract. 2007;78(3):355–9. https://doi.org/10.1016/j.diabres.2007.06.005.CrossRefPubMed

59.

Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications. 2007;21(3):166–71. https://doi.org/10.1016/j.jdiacomp.2006.02.006.CrossRefPubMed

60.

Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res. 2006;37(6):736–43. https://doi.org/10.1016/j.arcmed.2006.01.009.CrossRefPubMed

61.

Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50(4):891–4. https://doi.org/10.2337/diabetes.50.4.891.CrossRefPubMed

62.

Karimoei M, Pasalar P, Mehrabzadeh M, Daneshpour M, Shojaee M, Forouzanfar K, Razi F. Association between apolipoprotein E polymorphism and nephropathy in Iranian diabetic patients. Saudi J Kidney Dis Transpl. 2017;28(5):997–1002. https://doi.org/10.4103/1319-2442.215137.CrossRefPubMed

63.

Reis KA, Ebinç FA, Koç E, Demirci H, Erten Y, Güz G, Derici UB, Bali M, Söylemezoğlu O, Arınsoy T, Sindel S. Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail. 2011;33(5):469–74. https://doi.org/10.3109/0886022X.2011.568133.CrossRefPubMed

64.

Tien KJ, Tu ST, Chou CW, Yang CY, Hsiao JY, Shin SJ, Chen HC, Hsieh MC. Apolipoprotein E polymorphism and the progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol. 2011;33(3):231–8. https://doi.org/10.1159/000324561.CrossRefPubMed

65.

Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B, Gunduz C, Topcuoglu N, Ozgen G, Yilmaz C. The relationship of the apolipoprotein E gene polymorphism Turkish type 2 diabetic patients with and without nephropathy. J Endocrinol Invest. 2009;32(3):219–22. https://doi.org/10.1007/BF03346455.CrossRefPubMed

66.

Ma SW, Benzie IF, Yeung VT. Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism. Transl Res. 2008;152(3):134–42. https://doi.org/10.1016/j.trsl.2008.07.003.CrossRefPubMed

67.

Ilhan N, Kahraman N, Seçkin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct. 2007;25(5):527–32. https://doi.org/10.1002/cbf.1348.CrossRefPubMed

68.

Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(3):S228–32. https://doi.org/10.1016/j.diabres.2007.03.009.CrossRefPubMed

69.

Leiva E, Mujica V, Elematore I, Orrego R, Díaz G, Prieto M, Arredondo M. Relationship between apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract. 2007;78(2):196–201. https://doi.org/10.1016/j.diabres.2007.03.018.CrossRefPubMed

70.

Ng MC, Baum L, So WY, Lam VK, Wang Y, Poon E, Tomlinson B, Cheng S, Lindpaintner K, Chan JC. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T > C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet. 2006;70(1):20–8. https://doi.org/10.1111/j.1399-0004.2006.00628.x.CrossRefPubMed

71.

Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care. 2003;26(8):2416–20. https://doi.org/10.2337/diacare.26.8.2416.CrossRefPubMed

72.

Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J. Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem. 2003;254(1–2):353–8. https://doi.org/10.1023/a:1027364121738.CrossRefPubMed

73.

Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, Lee HY, Han DS. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transpl. 1999;14(9):2144–9. https://doi.org/10.1093/ndt/14.9.2144.CrossRef

74.

Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis. 1998;31(4):666–73. https://doi.org/10.1053/ajkd.1998.v31.pm9531184.CrossRefPubMed

75.

Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A, et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet. 1995;48(6):288–92. https://doi.org/10.1111/j.1399-0004.1995.tb04111.x.CrossRefPubMed

76.

Li J, Niu X, Li J, Wang Q. Association of PPARG gene polymorphisms Pro12Ala with type 2 diabetes mellitus: a meta-analysis. Curr Diabetes Rev. 2019;15(4):277–83. https://doi.org/10.2174/1573399814666180912130401.CrossRefPubMed

77.

Syed R, Jamil K, Asimuddin M, Alqahtani MS, Alshehri M, Mateen A, Wahab Ali Aduderman A, Ola MS, Malik A. Molecular & biochemical analysis of Pro12Ala variant of PPAR-γ2 gene in type 2 diabetes mellitus. Saudi J Biol Sci. 2020;27(9):2439–43. https://doi.org/10.1016/j.sjbs.2020.06.046.CrossRefPubMedPubMedCentral

78.

Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010;171(6):645–55. https://doi.org/10.1093/aje/kwp450.CrossRefPubMedPubMedCentral

79.

Luo W, Cao J, Li J, He W. Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. Exp Gerontol. 2008;43(3):154–63. https://doi.org/10.1016/j.exger.2007.11.002.CrossRefPubMed

80.

Thamer C, Haap M, Volk A, Maerker E, Becker R, Bachmann O, Machicao F, Häring HU, Stumvoll M. Evidence for greater oxidative substrate flexibility in male carriers of the pro 12 Ala polymorphism in PPARgamma2. Horm Metab Res. 2002;34(3):132–6. https://doi.org/10.1055/s-2002-23196.CrossRefPubMed

81.

Vodosek Hojs N, Bevc S, Ekart R, Hojs R. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. Antioxid (Basel). 2020;9(10):925. https://doi.org/10.3390/antiox9100925.CrossRef

82.

Parwani K, Mandal P. Role of advanced glycation end products and insulin resistance in diabetic nephropathy. Arch Physiol Biochem. 2023;129(1):95–107. https://doi.org/10.1080/13813455.2020.1797106.CrossRefPubMed

83.

Wang L, Teng Z, Cai S, Wang D, Zhao X, Yu K. The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol. 2013;8:118. https://doi.org/10.1186/1746-1596-8-118.CrossRefPubMedPubMedCentral

84.

Ding J, Zhu C, Mei X, Zhou Y, Feng B, Guo Z. Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis. Int J Clin Exp Med. 2015;8(5):7655–60.PubMedPubMedCentral

85.

Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51(2):165–76. https://doi.org/10.1016/j.pathol.2018.11.002.CrossRefPubMed

86.

Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561–72. https://doi.org/10.1194/jlr.P040501.CrossRefPubMedPubMedCentral

87.

Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):361–70. https://doi.org/10.1038/nrneph.2010.59.CrossRefPubMed

88.

Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H, Lai FM, Tong PC, Chan JC. Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation. Nephrol Dial Transpl. 2009;24(6):1889–95. https://doi.org/10.1093/ndt/gfn734.CrossRef

89.

Feng J, Wan G, Zhu X, Wang B, Yang Z. The apolipoprotein E (APOE) gene and the risk of diabetic nephropathy (DN): a meta-analysis in east Asian populations. Asian Biomed. 2010;4(2):329–35. https://doi.org/10.2478/abm-2010-0041.CrossRef

90.

Li Y, Tang K, Zhang Z, Zhang M, Zeng Z, He Z, He L, Wan C. Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep. 2011;38(5):3243–52. https://doi.org/10.1007/s11033-010-9999-z.CrossRefPubMed

91.

Shi J, Cheng Z, Qiu S, Cui H, Gu Y, Zhao Q, et al. ε2 allele and ε2-involved genotypes (ε2/ε2, ε2/ε3, and ε2/ε4) may confer the association of APOE genetic polymorphism with risks of nephropathy in type 2 diabetes: a meta-analysis. Lipids Health Dis. 2020;19(1):136. https://doi.org/10.1186/s12944-020-01307-6.CrossRefPubMedPubMedCentral

92.

Hu P, Qin YH, Jing CX, Lu L, Hu B, Du PF. Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations. Mol Biol Rep. 2011;38(1):489–94. https://doi.org/10.1007/s11033-010-0132-0.CrossRefPubMed

93.

Chen B, Cole JW, Grond-Ginsbach C. Departure from Hardy Weinberg equilibrium and genotyping error. Front Genet. 2017;8:167. https://doi.org/10.3389/fgene.2017.00167.CrossRefPubMedPubMedCentral

94.

Zintzaras E. Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol. 2010;25(8):553–60. https://doi.org/10.1007/s10654-010-9467-z.CrossRefPubMed

95.

Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13(7):840–8. https://doi.org/10.1038/sj.ejhg.5201410.CrossRefPubMed

Title: The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis
Authors: Binura Taurbekova
Kymbat Mukhtarova
Zhandos Salpynov
Kuralay Atageldiyeva
Antonio Sarria-Santamera
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Type 2 Diabetes
Microalbuminuria
Published in: BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-024-03859-6

Creatinine clearance/eGFR ratio: a simple index for muscle mass related to mortality in ICU patients

Open Access
Acute Kidney Injury
Research

The relationship between serum levels of LOX-1, hs-cTnT, NGAL, and renal function, and their diagnostic value in patients with chronic kidney disease: a retrospective study

Open Access
Chronic Kidney Disease
Research

Artificial intelligence and predictive models for early detection of acute kidney injury: transforming clinical practice

Open Access
Acute Kidney Injury
Review

Association between health-related hope and distress from restrictions in chronic kidney disease and dialysis

Open Access
Chronic Kidney Disease
Research

Effect of hemodiafiltration and hemodialysis on mortality of patients with end-stage kidney disease: a meta-analysis

Open Access
Research

Sirolimus-induced pulmonary toxicity without recurrence more than 8 years after everolimus replacement in a renal transplant patient with recurrent skin SCC: a case report

Open Access
Everolimus
Case Report

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content